ArticleScientific reports2026
Synergistic antioxidant and antibacterial hydrogel for accelerated wound healing through ROS scavenging and pathogen elimination.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of inflammatory cell activation in periodontitis-induced bone destruction and advances in targeted interventions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Wound management remains a significant clinical challenge due to bacterial infection, oxidative stress, and inflammation. To address these issues, we developed a multifunctional hydrogel, NO-GM/Fle@FD, by combining gelatin methacryloyl (GelMA), Pluronic F127 diacrylate (F127DA), the nitric oxide (NO) donor S-nitrosoglutathione (GSNO), and the antibiotic fleroxacin (Fle). The hydrogel allows rapid photopolymerization under 405 nm light, forming a robust network with controlled NO release and localized antibiotic delivery. In infected murine wound model, NO-GM/Fle@FD accelerated wound closure through three mechanisms: (1) infection suppression via fleroxacin-mediated bactericidal activity, (2) ROS scavenging to reduce oxidative damage, and (3) inflammatory modulation through sustained NO release. Histological analysis revealed complete re-epithelialization by day 10, reduced inflammation, and enhanced collagen deposition in the NO-GM/Fle@FD group. Immunofluorescence showed decreased IL-1β (pro-inflammatory) and increased IL-10 (anti-inflammatory), confirming the hydrogel's ability to resolve inflammation and counteract oxidative stress. This study demonstrates that NO-GM/Fle@FD effectively targets the infection-oxidative stress-inflammation triad, providing a promising therapeutic solution for treating infectious wounds, diabetic ulcers, burns, and other chronic complex wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.